New Clones on the Block

Although immune checkpoint blockade (ICB) has yielded striking clinical responses in subsets of cancer patients, the mechanism of action is still unclear. In a recent issue of Nature Medicine, Yost et al., 2019 report that the T cell clones that dominate the intra-tumoral T cell landscape after ICB...

Full description

Saved in:
Bibliographic Details
Published inImmunity (Cambridge, Mass.) Vol. 51; no. 4; pp. 606 - 608
Main Authors Acharya, Nandini, Anderson, Ana C.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 15.10.2019
Elsevier Limited
Subjects
Antigens
Cancer
Cell adhesion & migration
Clone Cells
Cloning
Gene expression
Genotype & phenotype
Humans
Immune checkpoint
Lymphocytes
Lymphocytes T
Melanoma
Neoplasms
Patients
Programmed Cell Death 1 Receptor
T cell receptors
T-Lymphocytes
Tumors
Online AccessGet full text

Cover

More Information
Summary:Although immune checkpoint blockade (ICB) has yielded striking clinical responses in subsets of cancer patients, the mechanism of action is still unclear. In a recent issue of Nature Medicine, Yost et al., 2019 report that the T cell clones that dominate the intra-tumoral T cell landscape after ICB are distinct from those prior to treatment, a phenomenon referred to by the authors as “clonal replacement.” Although immune checkpoint blockade (ICB) has yielded striking clinical responses in subsets of cancer patients, the mechanism of action is still unclear. In a recent issue of Nature Medicine, Yost et al., 2019 report that the T cell clones that dominate the intra-tumoral T cell landscape after ICB are distinct from those prior to treatment, a phenomenon referred to by the authors as “clonal replacement.”
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Commentary-1
ISSN:1074-7613
1097-4180
DOI:10.1016/j.immuni.2019.09.018